European Commission Approves Stelara® (Ustekinumab) For Treatment Of Adults With Moderately To Severely Active Crohn’s Disease
- EMEA Innovative Medicine
- European Commission Approves Stelara® (Ustekinumab) For Treatment Of Adults With Moderately To Severely Active Crohn’s Disease
European Commission Approves Stelara® (Ustekinumab) For Treatment Of Adults With Moderately To Severely Active Crohn’s Disease
-
X (Twitter) -
LinkedIn -
Pinterest -
Copy link